Coherus Biosciences Inc (NASDAQ:CHRS)’s share price was down 5.7% during trading on Monday . The stock traded as low as $10.55 and last traded at $10.75. Approximately 1,207,900 shares traded hands during trading, an increase of 27% from the average daily volume of 950,400 shares. The stock had previously closed at $11.40.

Several equities analysts have recently commented on CHRS shares. Citigroup reaffirmed a “buy” rating and set a $23.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, November 7th. Zacks Investment Research downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. ValuEngine raised shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $17.00 price target (down from $24.00) on shares of Coherus Biosciences in a research note on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $29.67.

The stock has a market capitalization of $666.37, a P/E ratio of -2.20 and a beta of 3.89. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46.

Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. analysts predict that Coherus Biosciences Inc will post -4.39 EPS for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the stock. Temasek Holdings Private Ltd bought a new position in Coherus Biosciences in the third quarter worth about $87,524,000. New York State Common Retirement Fund grew its holdings in Coherus Biosciences by 32.1% in the second quarter. New York State Common Retirement Fund now owns 43,600 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 10,599 shares during the period. Virtu KCG Holdings LLC purchased a new stake in Coherus Biosciences in the second quarter worth about $602,000. Northern Trust Corp grew its holdings in Coherus Biosciences by 13.8% in the second quarter. Northern Trust Corp now owns 464,056 shares of the biotechnology company’s stock worth $6,660,000 after purchasing an additional 56,122 shares during the period. Finally, FMR LLC grew its holdings in Coherus Biosciences by 0.3% in the second quarter. FMR LLC now owns 7,693,124 shares of the biotechnology company’s stock worth $110,396,000 after purchasing an additional 21,143 shares during the period. 81.10% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://theolympiareport.com/2018/01/24/coherus-biosciences-chrs-shares-down-5-7.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.